The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses
Open accessAbstract
T follicular helper (Tfh) cells are required to develop germinal center (GC) responses and drive immunoglobulin class switch, affinity maturation, and long-term B cell memory. In this study, we characterize a recently developed vaccine platform, nucleoside-modified, purified mRNA encapsulated in lipid nanoparticles (mRNA-LNPs), that induces high levels of Tfh and GC B cells. Intradermal vaccination with nucleoside-modified mRNA-LNPs encoding various viral surface antigens elicited polyfunctional, antigen-specific, CD4+ T cell responses and potent neutralizing antibody responses in mice and nonhuman primates. Importantly, the strong antigen-specific Tfh cell response and high numbers of GC B cells and plasma cells were associated with long-lived and high-affinity neutralizing antibodies and durable protection. Comparative studies demonstrated that nucleoside-modified mRNA-LNP vaccines outperformed adjuvanted protein and inactivated virus vaccines and pathogen infection. The incorporation of noninflammatory, modified nucleosides in the mRNA is required for the production of large amounts of antigen and for robust immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BNT162b2 is based on lipid-nanoparticle-formulated mRNA vaccine technology, which delivers precise genetic information of the immunogen to antigen-presenting cells and elicits potent immune responses 7 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The rapid and robust immunogenicity profile of the mRNA-1273 vaccine most likely results from an innovative structure-based vaccine antigen design,23 coupled with a potent lipid-nanoparticle delivery system, and the use of modified nucleotides that avoid early intracellular activation of interferon-associated genes.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These features of the mRNA composition and formulation have been associated with prolonged protein expression, induction of antigen-specific T-follicular helper cells, and activation of germinal center B cells.24”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [24]
In the citing paper
“Thus, in agreement with previous results (13, 25, 26), mRNA-1273 vaccination induces TH1- and TFH-skewed CD4 T cell responses.”
From Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates (2021) · cites this paper as [26]
In the citing paper
“In contrast, Pardi and colleagues reported that protein levels after intradermal injection of m1ψ-modified mRNA in mice were 20 times higher compared to sequence-optimized but unmodified mRNA.184”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [184]
In the citing paper
“The germinal center B cell response and its regulation by CD4+ T follicular helper (Tfh) cells are of key importance for high-affinity neutralization antibody titers and long-lasting B cell responses.53,54”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [54]
In the citing paper
“One study in mice showed that LNPs encapsulating nucleoside-modified mRNA circulated for longer and induced stronger TFH cell and germinal centre B cell responses than LNPs carrying unmodified mRNA200.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [200]
In the citing paper
“several studies have shown that i.m. delivery of 1mΨ-modified mRNA vaccines results in the rapid and potent induction of follicular T helper cells (Tfh) [71,72].”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [72]
In the citing paper
“Lipid nanoparticle–mRNA vaccines are also being investigated as influenza vaccines29,41,156,157,159,184,189–191, with some formulations in clinical trials (Table 1).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [190]
In the citing paper
“Lipid nanoparticle–mRNA formulations are further being explored for Zika virus vaccines38,190,192–194.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [190]
In the citing paper
“Furthermore, lipid nanoparticle–mRNA vaccines have been tested against other viruses in animal models, including human immunodeficiency virus28,144,181,190, Powassan virus195, Venezuelan equine encephalitis virus196, dengue virus73 and Ebola virus197.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [190]
In the citing paper
“Additionally, the robust and sustained antigen expression of nucleoside-modified mRNA was associated with more optimal antibody responses compared to unmodified mRNA [12,13].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationVictora, G. D., & Nussenzweig, M. C. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075032 · Cited by 1,878
T follicular helper cell differentiation, function, and roles in disease
Crotty, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.004 · Cited by 1,847
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Self-citationPotent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationModified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 531
Development of mRNA Cancer Vaccines: Delivery Strategies and Immunogenicity Optimization
Ali, A. (2025) · Current Medical Science · doi:10.1007/s11596-025-00127-y · Cited by 4
Technological advances in mRNA delivery and engineering for therapeutic cancer vaccines
Uchida, S. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf199 · Cited by 4
Jefferies, W. A., Choi, K. B., Ribeca, P., Kari, S., Young, J. B., Hui, E., Qi, S. Y., Garrovillas, E., Fan, J., Cho, B. M. Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66252-3 · Cited by 5
mRNA Vaccines for Cancer Treatment
Torphy, R. J., Balachandran, V., & Soares, K. C. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.006 · Cited by 3
Application of nanoparticles in antibody drug delivery
Xiefukaiti, W., Zhu, Q., Dolkun, N., & Xiao, X. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1759915 · Cited by 3
A prognostic insight of the mRNA vaccine against antibiotic-resistant bacteria
Abusalah, M. A. H., Choudhary, P., Bargui, H., Ahmed, N., Abusalah, M. A. H. A., & Choudhary, O. P. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001970 · Cited by 3
Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 3
Improving the Efficacy of Cancer mRNA Vaccines
Kirtane, A. R., & Traverso, G. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000764 · Cited by 3
Thakur, A., Wadhwa, A., Lokras, A. G., Müllertz, O. A. O., Christensen, D., Franzyk, H., & Foged, C. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.04.005 · Cited by 3
Liposomes: from August Wassermann to Vaccines Against COVID-19
Grygorieva, G., Pylypenko, D., & Krasnopolsky, Y. (2023) · ADMET & DMPK · doi:10.5599/admet.1926 · Cited by 4
Takotsubo Syndrome and Vaccines: A Systematic Review
Li, C., Li, P., Peddibhotla, B., Teng, C., Shi, A., Lu, X., Cai, P., Dai, Q., & Wang, B. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14719 · Cited by 3
Self-citationZimmermann, L., & Erbar, S. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_5 · Cited by 3
Mutants and Variants of SARSCoV-2 Across the Globe - A Comprehensive Review
Kaushal, A. (2021) · ACTA SCIENTIFIC MICROBIOLOGY · doi:10.31080/asmi.2021.04.0840 · Cited by 3
Prioritizing the First Doses of SARS-CoV-2 Vaccine to Save the Elderly: The Case Study of Italy
Pontrelli, G., Cimini, G., Roversi, M., Gabrielli, A., Salina, G., Bernardi, S., Rocchi, F., Simonetti, A., Giaquinto, C., Rossi, P., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.684760 · Cited by 3
Editorial: Adaptive immunity to respiratory pathogens
Iwanaga, N., Devarajan, P., & Shenoy, A. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174178 · Cited by 3
A Historical Overview on mRNA Vaccine Development
Verbeke, R., Cheng, M. H. Y., & Cullis, P. R. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch1 · Cited by 5
Endogenous antigen processing promotes mRNA vaccine CD4 + T cell responsesPreprint
Rood, J. E., Yoon, S. K., Heard, M. K., Carro, S. D., Hedgepeth, E. J., O'Mara, M. E., Hogan, M. J., Le, N., Muramatsu, H., Lam, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.11.642674 · Cited by 3
Self-citationEfficient Cas9 nuclease-based editing in skeletal muscle via lipid nanoparticle deliveryPreprint
Iyer, S., Daman, K., Sun, Y., Tutto, A. A., Holbrook, S. E., Joynt, A. T., Yan, J., Ambegaokar, P. P., Guo, D., Liu, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.12.653518 · Cited by 3
Khatri, J., Tahboub, I. N., Anwar, K., Masoudi, M., Graffeo, V. A., & Jamil, M. O. (2024) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096241231645 · Cited by 2
Assessment of the Adjuvant Effects of Lentinan on the Tuberculosis Subunit Vaccine BG
Zhou, S., Hou, Y., Zhang, X., Lv, Z., Hu, Q., Yang, X., & Niu, H. (2025) · Vaccines · doi:10.3390/vaccines13060597 · Cited by 2
Ren, K., Yu, C., Yang, Q., Zhang, Q., & Li, P. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503644 · Cited by 3
Empty lipid nanoparticles (eLNPs) with adjuvant activity induce potent immune responses
Qiu, D., Yan, S., Chen, R., Wu, S., Nie, M., Yang, M., Liu, Y., Wu, Y. Y.-C., Xiong, H., Yuan, Q., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70340 · Cited by 2
Detection of spike protein in term placentas of COVID-19 vaccinated and/or SARS-CoV-2 infected women
Bartmann, C., Schmidt, P. V., Mörz, M., Schwab, M., Rehn, M., Blau-Schneider, B., Wöckel, A., & Kämmerer, U. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344185 · Cited by 4
Ona, N. A., Zhang, D., Lindesmith, L. C., Park, W., Meshanni, J. A., Berkihiser, S., Vasserman, J. A., Toshtzar, S., Moore, N. C., Williams, B., et al. (2026) · Science Advances · doi:10.1126/sciadv.adv1554 · Cited by 2
Self-citationQiao, N., Chen, J., Liu, Y., Chen, Z. J., & Chen, S. J. (2026) · MedScience · doi:10.1007/s11684-026-1210-6 · Cited by 3
Foot-and-mouth disease virus-like particle mRNA vaccine induces strong humoral and cellular immunity
Liu, H., Zhang, Y., Mu, S., Hou, F., Jiang, L., Wang, Z., Dong, H., Mehdi, M. M., Guo, H., & Sun, S. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-13812-2 · Cited by 2
Perspective Chapter: Next-Generation Vaccines Based on Self-Amplifying RNA
Nafian, F., Nafian, S., Soleymani, G., Pourmanouchehri, Z., Kiyanjam, M., Jalaei, S. B., Jeyroudi, H., & Mohammdi, S. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.101467 · Cited by 2
Antiviral potential of nanomaterials: Novel solutions for emerging challenges
Azab, W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821637-8.00003-1 · Cited by 2
Human Immunodeficiency Virus Vaccine
Graciaa, D. S., Walsh, S. R., & Rouphael, N. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.04.004 · Cited by 3
mRNA Vaccines: Immunology and Present and Future Potential
Khan, O. F., Couture‐Senécal, J., Lau, Y. M. A., Oproescu, A.-M., Pang, J., Tilstra, G., & Walz, B. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-62772-9_5 · Cited by 2
Ye, L., Wang, T., Wu, S., Liu, F., Liu, F., Wang, C., & Hu, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113602 · Cited by 2
Wu, Y., Jia, X., Wu, N., Zhang, X., Wu, Y., Liu, Y., Zhou, M., Shen, Y., Li, E., Wang, W., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.030 · Cited by 2
Klingel, H., Krüttgen, A., Imöhl, M., & Kleines, M. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.1.60 · Cited by 3
Personalized vaccines, novel vaccination technologies, and future prospects
Vasudevan, S. S., Kandrikar, T. Y., Sayyed, A. A., Sridhar, S., Prasad, A., Khandelwal, S., Baniya, S., Miguela, C. A. C., & Gondaliya, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00024-2 · Cited by 2
Are long-term influenza vaccines possible and how do we discover them?
Kim, J. K., Kang, S., Compans, R. W., & Wang, B. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1828859 · Cited by 2
Immunogenicity of SARS-CoV-2 trimetric spike protein associated to Poly(I:C) plus AlumPreprint
dos-Santos, J. S., Firmino-Cruz, L., da Fonseca-Martins, A. M., Oliveira-Maciel, D., Pérez, G., Pereira, V. A. R., Dumard, C. H., Guedes-da-Silva, F. H., Santos, A. C. V., Leandro, M. D. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.05.461434 · Cited by 2
Jeger‐Madiot, R., Planas, D., Staropoli, I., Kervevan, J., Mary, H., Collina, C., Fonseca, B. F., Debarnot, H., Robinot, R., Gellenoncourt, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.02.578553 · Cited by 2
Moriyama, M., Rodrigues, G. R., Wang, J., Hudak, A., Dong, H., Homer, R., Weissman, D., Ma, S., & Iwasaki, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.10.616291 · Cited by 2
Self-citationZhu, Y., Yao, Z., Li, S.-H., Ma, J., Wei, C. Y., Yu, D., Stelzel, J. L., Ni, B. Y. X., Miao, Y., Batavia, K. V., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.27.633179 · Cited by 2
Sengupta, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91814-5.00007-6 · Cited by 1
Decoding trends in mRNA vaccine research: A comprehensive bibliometric study
Zhang, C., Wang, Y., Peng, J., Wen, X., Zhang, Y., Li, K., Du, H., & Hu, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2355037 · Cited by 1
The mRNA vaccine contributors: Assessing their impact through a mainstream lens
Ho, M. H., Liu, J. S., Wang, W., & Chuang, T. C. (2025) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2025.124200 · Cited by 1
Human CD4 T cells are a functional target for lipid nanoparticle-based mRNA vaccines
Kim, S., Felgner, J. H., Soto, M. S., Hitchcock, L., Silzel, E. K., Beares, H., Hwang, M. J., Yates, T. B., Cheng, S., Joloya, E. M., et al. (2025) · mBio · doi:10.1128/mbio.02254-25 · Cited by 2
N1MΨU-modified mRNA vaccines break the mold in fish by enhancing innate immune activation
Porter, D., Jouneau, L., Peruzzi, M., Collet, B., Verrier, B., & Boudinot, P. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102862 · Cited by 2
A review on RNA technologies renaissance: a paradigm shift shaping the future of modern medicine
Singh, S. P., Mundlia, P., Sharma, A. M., Kaur, H., Chaubey, B., Khajuria, A., Chatterjee, M., Jaiswal, P. K., Ranawat, P., Singh, G., et al. (2026) · Next Bioengineering · doi:10.1016/j.nxbio.2026.100016 · Cited by 1
Iyer, S. R., Daman, K., Sun, Y., Tutto, A. A., Holbrook, S. E., Joynt, A. T., Yan, J., Ambegaokar, P. P., Guo, D., Liu, P., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.010 · Cited by 6
Ojha, C. R., Rovito, S. W., Banoth, B., Kim, H., Jones, J. C., Alameh, M., Chen, P.-L., Webby, R. J., Weissman, D., & Russell, C. J. (2026) · Viruses · doi:10.3390/v18040467 · Cited by 1
Self-citationIsmail, J., Tamilselvan, B., Rubsamen, M., Petrosky, J., Richardson, B., Zagore, L. L., Oyebanji, O. A., Keresztesy, D., Payne, M., Wilk, D. J., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115730 · Cited by 1
Rochman, Y., Melamed, J. R., Klingler, A. M., Kotliar, M., Rochman, M., Caldwell, J. M., Felton, J. M., Osswald, G. A., Muscat-Rivera, J., Kegel, M., et al. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.05.023 · Cited by 1
Self-citationNguyen, V. H., Settembre, E. C., Youhanna, J. E., Beck, E. C., de Velde, N. V., & Joshi, K. (2026) · Vaccines · doi:10.3390/vaccines14090750 · Cited by 1
Adjuvants, the Elephant in the Room for RNA Vaccines
D’haese, S., den Roover, S., & Aerts, J. L. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_12 · Cited by 1
Praet, J. T. V., Groote, M. D., Bacquer, D. D., Verhalleman, E., Welvaert, Z., Emmerechts, J., Reynders, M., & Vriese, A. S. D. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac585 · Cited by 1
A case of covaxin-induced focal sclerosingglomerulonephritis (collapsing variety)
Mahajan, M., Goswami, S., Pahwa, N., Malviya, V., Shukla, V., & Chhabra, T. (2022) · BOHR International Journal of General and Internal Medicine · doi:10.54646/bijgim.2022.10 · Cited by 1
mRNA vaccines against arthropod-borne orthofaviviruses
Wang, Z., Chi, H., Deng, Y., & Han, X. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0261 · Cited by 1
Integrating Context of Tumor Biology and Vaccine Design to Shape Multidimensional Immunotherapies
Wang, N. S., & Maine, C. J. (2020) · Future Drug Discovery · doi:10.4155/fdd-2019-0031 · Cited by 1
Nucleic acid-based vaccines of COVID-19 and their delivery systems
Yang, H., Zhang, M., Weng, Y., Cao, Y., & Huang, Y. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0051 · Cited by 1
Fu, J., Feng, S., Du, B., Dong, H., Lin, J., & Yongfeng, J. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0376 · Cited by 1
Glomerular endothelial injury following vaccination for SARS-CoV-2
Tanemoto, M., Kimura, T., & Kanetsuna, Y. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab283 · Cited by 1
Baldo, B. A., & Pham, N. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-51740-3_16 · Cited by 1
A Comprehensive Review of Vaccines against Covid-19
Minh, P. H., Linh, V. K., Hải, N. T., & Tùng, B. T. (2021) · VNU Journal of Science Medical and Pharmaceutical Sciences · doi:10.25073/2588-1132/vnumps.4365 · Cited by 1
Risk Assessment of COVID-19 Vaccination Among Childbearing Women.
Tsiorou, K., & Sarantaki, A. (2022) · PubMed Central · doi:10.26574/maedica.2022.17.2.449 · Cited by 1
mRNA Vaccines: A Prospective Analysis of Long-term, Multi-target, and Autoimmune DisordersPreprint
Niazi, S. K. (2023) · Preprints.org · doi:10.20944/preprints202310.1981.v1
Editorial: Post COVID-19: the nucleoside-modified messenger RNA (modRNA) platform
Roncati, L., & Huo, Q. T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1324610 · Cited by 1
Modified or Unmodified mRNA Vaccines? – The Biochemistry of Pseudouridine and mRNA Pseudouridylation
Morais, P., & Yu, Y. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch3 · Cited by 2
Lusso, P. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch9 · Cited by 1
The Techniques Used on the Development of COVID-19 Vaccine
Su, J. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202127101037
mRNA Vaccine: An Advanced and Transformative Technology for Vaccine Development
Kushwaha, V., Anuprabha, & Sobti, R. C. (2021) · Springer eBooks · doi:10.1007/978-981-16-5105-2_15
Louten, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90565-7.00014-9
Messenger RNA Based Vaccines and Their immunological effect on diseases
Hasan, O. M. (2022) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v22i2.836
Lipid Nanoparticles to Harness the Therapeutic Potential of mRNA for Cancer Treatment
Guevara, M. L., Persano, F., & Persano, S. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_14
da Silva, J. R. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2021.tde-17032022-102622
Appraisal of Some of the Key Postulates Underlying mRNA Vaccines
Mueller, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-18903-6_2
Parahydrogen‐Induced Polarization of a Labeled, Cancer‐Targeting DNA Aptamer
Brenske, K., Emondts, M., Hörnig, S. T., Panitz, S., Pieper, M. I., Ligori, A., Schacht, A., Henkel, J., Klankermayer, J., & Herrmann, A. (2023) · Angewandte Chemie · doi:10.1002/ange.202300531
Tong, T., D’Addabbo, A., Xu, J., Chalwa, H., Nguyen, A., Ochoa, P., Crispin, M., & Binley, J. Μ. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.02.543368
Weiner, D. B., Jansen, K. U., & Villafana, T. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00068-2
Experiments and Clinical Trials Against Infectious Diseases
Lemonnier, J., & Lemonnier, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-39300-6_12
Incorporation of Pseudouridine into RNA for Biochemical and Biophysical Studies
Sanford, T. C., Riley, A., Clawson, M., Raasch, K., Oyebamiji, R., & Sumita, M. (2023) · RNA technologies · doi:10.1007/978-3-031-36390-0_25
ATENÇÃO FARMACÊUTICA NO USO DO METILFENIDATO EM CRIANÇAS COM DIAGNÓSTICO DE TDAH
Silva, A. V. F., Maciel, Y. G., de Vasconcelos, T. C. L., & Gomes, C. L. (2024) · doi:10.22533/at.ed.3442405015
EXCIPIENTES PARA MEDICAMENTOS SÓLIDOS ORAIS: UMA ANÁLISE DA PRODUÇÃO CIENTÍFICA BRASILEIRA
Gama, N. C. S., de Queiroz, M. M., Braz, R. D., dos Santos, K. V. F., Nova, M. A. V., Silva, M. T. A., Barreto, I. C., Filho, J. M. T. D. A., do Nascimento, T. G., & Costa, S. P. M. (2024) · doi:10.22533/at.ed.3442405016
Rodrigues, F. D., Galvão, F., Rolão, D. L. J., dos Santos, J. V. D. A., Dantas, F. G. D. S., & de Oliveira, K. M. P. (2024) · doi:10.22533/at.ed.3442405011
OS DESAFIOS DA NANOTECNOLOGIA EM MEDICAMENTOS
Guedes, C. P., de Lima, M. E. M., & Dantas, L. A. (2024) · doi:10.22533/at.ed.3442405014
DIFICULDADES NO DESENVOLVIMENTO DE VACINAS CONTRA O HIV
Santana, M. L., de Vasconcelos, T. C. L., & Lima, C. G. (2024) · doi:10.22533/at.ed.3442405013
O IMPACTO DO ÔMEGA 3 NO TRATAMENTO DE PACIENTES COM SINDROME METABÓLICA
Barbosa, M. J., da Silva, I. J. S., Vasconcelos, T. C. D. L., & Lima, C. G. (2024) · doi:10.22533/at.ed.3442405012
mRNA vaccines: a promising solution for incurable diseases
Ge, H., Hei, Y., & Wu, J. (2024) · International Conference on Biological Engineering and Medical Science (ICBioMed) · doi:10.1117/12.3021657
Farmácia: fronteiras na pesquisa e desenvolvimento
Pessoa, D. L. R. (2024) · doi:10.22533/at.ed.344240501
Immune Responses to mRNA Vaccine
Exposito, J., Monge, C., Arruda, D. C., & Verrier, B. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch2
Nanomedicine’s Role in the COVID-19 Vaccine Development and Optimization
Kumar, J., Malhotra, J., Yadav, A. S., & Bhati, A. S. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_3
Limeres, M. J., Gambaro, R. C., Svensson, M., Ghazi, S. F.-E., Pretsch, L., Frank, D., Islan, G. A., Berti, I. R., Bros, M., Tam, Y. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.12.636533
Self-citationAbuBakr, N., Mubarak, R. T., Haggag, T., & Khaled, H. (2025) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2025.102393
Toyonaga, H., Cheng, L., & Tanaka, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00982
T Cell Dysfunction in HIV Infection and Its Therapeutic Prospects
王, 宣. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15103003
Liu, S., Gong, Z. L., Wang, P., Chen, F., Fu, X., Fan, H., Li, Y., Han, X., Chen, J., Zhang, L., et al. (2025) · Vaccines · doi:10.3390/vaccines13111155
COVID-19 drug delivery: Current achievements and the impact of nanocarriers
Jayashree, S., Sonia, K., Gopal, M., Sharmili, S. A., & Vijayakumar, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33002-5.00023-3
Canti, L., Humblet‐Baron, S., Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., Servais, S., Willems, É., Ehx, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16864787
Watanabe, S., Zheng, S., & Rashidi, A. (2022) · Figshare · doi:10.6084/m9.figshare.19549586
Rotavirus induces mucosal B-cell responses through the TLR3/TRIF and MAVS pathways
Zhang, R., Yang, Y.-Y., Yang, W.-R., Yang, W.-R., Azeem, R. M., Niu, F.-X., Yang, Y.-X., Hu, M.-J., Shi, C.-W., Yang, G.-L., et al. (2026) · Veterinary Microbiology · doi:10.1016/j.vetmic.2026.110910
Akkineni, S., Pasupuleti, D., Gulani, M. A., Harsoda, Y., D’Souza, M. J., Chbib, C., & Uddin, M. N. (2026) · Vaccines · doi:10.3390/vaccines14030215
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Exploration structurale de la maturation des ARN
Meynier, V. (2023) · theses.fr (ABES) · doi:10.70675/73fb7d4ez0e4az4eafzbce9z244d7edb23e5
Metadata
- Authors
- Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., LaBranche, C. C., Montefiori, D. C., Lobby, J. L., Saunders, K. O., Liao, H.-X., Korber, B. T., Sutherland, L. L., Scearce, R. M., Hraber, P. T., Tombácz, I., Muramatsu, H., Ni, H., Balikov, D. A., Li, C., Mui, B. L., Tam, Y. K., Krammer, F., Karikó, K., Polacino, P., Eisenlohr, L. C., Madden, T. D., Hope, M. J., Lewis, M. G., Lee, K. K., Hu, S.-L., Hensley, S. E., Cancro, M. P., Haynes, B. F., & Weissman, D.
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- University of Washington (US)
- Duke Medical Center (US)
- Children's Hospital of Philadelphia (US)
- Los Alamos National Laboratory (US)
- Department of Medicine, University of Pennsylvania, Philadelphia, PA 1
- Acuitas Therapeutics (Canada) (CA)
- Icahn School of Medicine at Mount Sinai (US)
- BioNTech (Germany) (DE)
- Bioqual (US)
- Corresponding author
- Weissman, Drew
- ORCID
- Pardi, Norbert
- Hogan, Michael J.
- Naradikian, Martin S.
- Parkhouse, Kaela
- Cain, Derek W.
- Jones, Letitia
- Moody, M. Anthony
- Verkerke, Hans P.
- Willis, Elinor
- LaBranche, Celia C.
- Montefiori, David C.
- Lobby, Jenna L.
- Saunders, Kevin O.
- Liao, Hua-Xin
- Korber, Bette T.
- Sutherland, Laura L.
- Scearce, Richard M.
- Hraber, Peter T.
- Tombácz, István
- Muramatsu, Hiromi
- Ni, Houping
- Balikov, Daniel A.
- Mui, Barbara L.
- Tam, Ying K.
- Krammer, Florian
- Karikó, Katalin
- Eisenlohr, Laurence C.
- Lewis, Mark G.
- Lee, Kelly K.
- Hu, Shiu-Lok
- Hensley, Scott E.
- Cancro, Michael P.
- Haynes, Barton F.
- Weissman, Drew
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2018-05-08
- Volume
- 215
- Issue
- 6
- Pages
- 1571-1588
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5987916
- OpenAlex
- W2802953285
- Cited by
- 530
- References
- 56
- Citations by year
- 2026: 58 · 2025: 51 · 2024: 77 · 2023: 65 · 2022: 93 · 2021: 118 · 2020: 40 · 2019: 22 · 2018: 6
- FWCI
- 19.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- National Institutes of Health (5T32AI055428-12, U19 AI109946-01, 5R01GM099989-04)
- U.S. Department of Defense (PR130769)
- National Institute of Allergy and Infectious Diseases (R01-AI050484, R01-AI124429, R01-AI084860, HHSN27201100016C)
- Gates Foundation (CAVD 0PP1033102, CAVD OPP1033102)
- Takeda Pharmaceuticals U.S.A
- Center for Global Health (OPP1126258)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- nucleoside-modified mRNA, mRNA vaccines, lipid nanoparticles, T follicular helper cells, germinal center B cells, intradermal vaccination, neutralizing antibodies, affinity maturation, memory B cells, viral surface antigens, non-human primates, vaccine adjuvants
- MeSH terms
- Adjuvants, Immunologic, Animals, Antibody Formation, Antigens, B-Lymphocytes, T-Lymphocytes, Helper-Inducer, Lipids, Macaca mulatta, Nucleosides, RNA, Messenger, Time Factors, Vaccination, Germinal Center, Protein Subunits, Vaccines, Subunit, Nanoparticles, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
